Beta Bionics faces a class action lawsuit for allegedly misleading investors about the safety and effectiveness of its iLet Bionic Pancreas insulin pump. The company claimed FDA concerns were minor and unrelated to device safety, but the FDA's warning letter revealed serious device malfunctions causing dangerous insulin overdoses and life-threatening events. The stock price dropped from $31.99 to $12.89 after these disclosures. Investors who bought Beta Bionics stock between July 30, 2025, and February 24, 2026, may join the lawsuit before the November 3, 2026 deadline.
Sagimet Biosciences has initiated a crucial Phase 3 clinical trial in the U.S. for denifanstat, an oral treatment targeting moderate to severe acne. The trial, named AURORA, aims to enroll around 800 patients, including adolescents, to support regula...
Nokia reported third-quarter 2026 earnings per share of $0.10, surpassing the $0.08 estimate, and revenue of $5.78 billion, exceeding the $5.72 billion forecast. The company's AI and cloud sales surged 123%, driven by high demand for its IP Networks ...
RingCentral will announce its Q3 2026 earnings on October 22, with analysts forecasting earnings per share between $1.27 and $1.28 and revenue around $667 million. This represents a 12.4% increase in earnings and 4.4% growth in revenue compared to th...
Freddie Mac reported that the average 30-year fixed mortgage rate fell to 7.32% as of October 22, 2026, down from 7.40% the previous week. This decline offers some relief to prospective homebuyers facing higher borrowing costs compared to last year, ...
Canada's 5G device market is forecasted to expand from USD 10 billion in 2026 to USD 15.2 billion by 2031, growing at 8.7% annually. Growth is fueled by mid-band spectrum deployment, federal connectivity programs, and rising enterprise adoption of ad...
